These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
00904-7505 Market Analysis and Financial Projection
The drug associated with NDC 00904-7505 is Bupropion Hydrochloride Extended-Release 150 mg tablets, produced by Major Pharmaceuticals. This atypical antidepressant is widely used for major depressive disorder and smoking cessation. Below is a detailed market analysis and price projection based on available data:
Market Analysis
Current Market Size and Growth
The global Bupropion Hydrochloride Extended-Release tablets market was valued at $1.2 billion in 2024 and is projected to reach $1.8 billion by 2033, growing at a CAGR of 5.6% [10][15].
Growth drivers include rising mental health disorders (e.g., 21 million U.S. adults experienced major depression in 2023) and expanded use in smoking cessation therapies [10][13].
Competitive Landscape
Major Pharmaceuticals competes with brands like Wellbutrin SR and generic manufacturers such as A-S Medication Solutions and Denton Pharma.
Key trends: Shift toward cost-effective generics post-patent expirations and R&D investments to improve bioavailability and reduce side effects [3][13].
Regional Dynamics
North America dominates due to high mental health awareness and healthcare expenditure.
Europe and Asia-Pacific show accelerating growth driven by improving healthcare infrastructure and rising depression rates [7][15].
Regulatory and Economic Factors
The Medicare Drug Price Negotiation Program (effective 2026) may pressure list prices, though Bupropion’s generic status reduces immediate impact [16].
Production costs for active pharmaceutical ingredients (APIs) averaged $72,900–$77,500/MT in 2023, influencing wholesale pricing [7][18].
Price Projections
Factor
Short-Term (2025–2027)
Long-Term (2028–2035)
List Price/Unit
$0.08–$0.09 (4–6% annual increase) [5]
Stabilization near $0.10 due to generic competition [5][16]
Potential decline with scaled generic production [13]
Market Demand
Steady growth (CAGR ~5.6%) [10]
Slower growth as novel antidepressants enter market [4][15]
Key Risks and Opportunities
Opportunities: Expansion into emerging markets, development of combo therapies for comorbid conditions [13][15].
Risks: Price erosion from generics, regulatory scrutiny on side effects (e.g., seizure risks) [10][15].
“The Bupropion SR market remains resilient due to its dual efficacy in depression and smoking cessation, though long-term growth hinges on overcoming generic saturation.” [15]
This analysis synthesizes pricing data, regulatory shifts, and competitive dynamics to project stable yet moderated growth for NDC 00904-7505.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
